Compare MEC & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | LRMR |
|---|---|---|
| Founded | 1945 | N/A |
| Country | United States | United States |
| Employees | 2200 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 316.6M |
| IPO Year | 2019 | N/A |
| Metric | MEC | LRMR |
|---|---|---|
| Price | $17.82 | $3.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $22.00 | $16.71 |
| AVG Volume (30 Days) | 182.8K | ★ 1.1M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $533,523,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.93 | N/A |
| P/E Ratio | $30.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.72 | $1.61 |
| 52 Week High | $19.77 | $5.37 |
| Indicator | MEC | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 40.19 |
| Support Level | $17.30 | $3.31 |
| Resistance Level | $19.77 | $4.01 |
| Average True Range (ATR) | 0.80 | 0.24 |
| MACD | -0.16 | -0.05 |
| Stochastic Oscillator | 13.25 | 10.07 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.